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Introduction: The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines
for Glomerulonephritis recommend that patients with membranous nephropathy (MN) at risk for progression receive immunosuppressive therapy (IST), usually after 6 months of observation. A cyclophosphamide (CYC) or calcineurin inhibitor (CNI)–based regimen is recommended as ﬁrst-line IST. However,
the extent to which KDIGO recommendations are adopted in practice remains largely unknown.
Methods: We evaluated prescribing practice among patients with primary MN (diagnosed 2010–2018)
enrolled in the Cure Glomerulonephropathy Network (CureGN) cohort study. We also evaluated the
availability of testing for phospholipase A2 receptor (PLA2R) in the contemporary era.
Results: Among 361 patients (324 adults and 37 children) with MN who were IST-naïve at biopsy and had at
least 6 months of follow-up, 55% of adults and 58% of children initiated IST <6 months after biopsy. Of these,
1 in 5 had no indication for (i.e., urine protein-to-creatinine ratio [uPCR] <4 g/g) or an apparent contraindication to (i.e., an estimated glomerular ﬁltration rate [eGFR] <30 ml/min per 1.73 m2) IST. As ﬁrst-line IST,
half of treated patients received either CYC (16% of adults; 0% of children) or a CNI (40% and 46%, respectively), whereas 1 in 5 received corticosteroid monotherapy (20% and 27%, respectively) and 1 in 6 rituximab
(15% and 15%, respectively). More than 80% of surveyed centers had access to PLA2R testing.
Conclusion: These ﬁndings suggest that providers are not aware of, or lack conﬁdence in, current KDIGO
guidelines for MN. Treatment patterns observed in this cohort might critically inform the drafting of
planned updates to KDIGO guidelines.
Kidney Int Rep (2019) 4, 1725–1734; https://doi.org/10.1016/j.ekir.2019.09.005
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rimary MN is a leading cause of nephrotic syndrome in adults worldwide but is much rarer in
children.1,2 The clinical presentation and natural history of MN are highly variable, with up to one-third of
patients entering remission spontaneously without

P
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treatment,3,4 but many others experiencing progressive
decline in kidney function.5,6 The KDIGO clinical practice guidelines for MN recommend initiation of IST after 6 months of observation if patients have not entered
remission spontaneously,7 or sooner if severe disease
complications develop. However, it is recommended
that IST be avoided entirely in patients expected to
have a good prognosis without IST (i.e., <4 g/24 hours
of proteinuria) or in those whose disease is already too
advanced (i.e., those with a serum creatinine >3.5 mg/
dl or an eGFR <30 ml/min per 1.73 m2). The KDIGO
guidelines also recommended speciﬁc ﬁrst- and
second-line IST approaches based on limited data
from randomized controlled trials. However, the extent
to which these recommendations regarding the necessity, timing, and choice of IST in MN are adopted in
clinical practice remains unknown.
Because KDIGO guidelines for glomerulonephritis
were published in 2012, understanding of the pathophysiology and treatment of MN has advanced
considerably, in particular since the discovery that
M-type PLA2R antibodies are implicated in most cases
of primary MN.8–13 Accordingly, based on a recent
KDIGO consensus report, nearly all MN treatment
recommendations will have to be revisited.14 The discovery of anti-PLA2R has also sparked new interest in
B-cell–targeted IST strategies for MN.15,16 However,
contemporary practices with respect to testing for
PLA2R antigen in biopsy specimens and/or PLA2R
antibodies in serum, and prescribing of B-cell–targeted
IST strategies, among patients with biopsy-proven
primary MN, has not to our knowledge been reported.
Recognizing these knowledge gaps, our study aimed
to describe contemporary practice patterns with
respect to the timing and choice of IST in adults and
children with MN enrolled in the CureGN, to compare
observed practice patterns with current KDIGO treatment guidelines, and to determine accessibility to
PLA2R antigen/antibody testing among nephrologists
caring for patients with MN.
METHODS
Study Design and Population
CureGN is an ongoing international cohort study17
aiming to enroll 2400 adults and children with minimal change disease, focal segmental glomerulosclerosis,
MN, or IgA nephropathy, diagnosed by kidney biopsy
within the 5 years before study enrollment. Institutionalized patients, those with end-stage renal disease
at screening, or with diabetes, a prior organ/hematopoietic transplant, hepatitis B or C, HIV, malignancy, or
systemic lupus erythematosus at time of biopsy, are
excluded. Patients are recruited from 70 sites (65 in the
1726

United States, 3 in Canada, 1 in Italy, and 1 in Poland)
and are identiﬁed either through receiving nephrology
care at one of these sites or through referral from a
primary treating nephrologist in the community.
Enrollment and subsequent annual visits are conducted
in person; interval 4-monthly study visits can be
conducted in person or remotely (i.e., by telephone or
e-mail). Research coordinators conduct all study visits
and enter data, under the supervision of the site clinical
principal investigator.
All children and adults with MN enrolled in CureGN by June 5, 2018, were considered for study inclusion. We restricted our study population to
patients who were naïve to IST before kidney biopsy
so as to focus on patients we were conﬁdent were
prescribed IST for management of newly diagnosed
glomerular disease and not another indication. However, because it is common practice to treat children
with nephrotic syndrome with glucocorticoids (GCs)
empirically before performing a kidney biopsy, we
regarded children who had received a maximum of 6
weeks of GC monotherapy immediately before kidney
biopsy as also being treatment-naïve. All study subjects provided written informed consent. This study
was approved by each institutional review board in
agreement with the Declaration of Helsinki.
Data Collection and Deﬁnitions
Immunosuppressive Medications

At study enrollment, data were collected regarding all
ISTs used to treat glomerular disease before study
enrollment, including start and stop dates. Thereafter,
medication lists were updated at each study visit. We
categorized IST as follows: GC alone, CNI-based therapy, CYC-based therapy, rituximab (RTX)-based therapy, mycophenolate mofetil (MMF)–based therapy, or
combination IST. If GCs were prescribed concurrently
with another IST, we considered this to be therapy
based on the other IST. Therapies started within 30
days of one another were considered part of the same
regimen.
Other Demographic,
Measures

Clinical,

and

Laboratory

We deﬁned adults as those $18 years at time of biopsy.
Glomerular disease subtypes were deﬁned according to
their original biopsy report diagnosis. Whenever
available, laboratory values measured between time of
symptom onset and time of enrollment were collected
and recorded. The eGFR was calculated using the
Bedside Schwartz formula in children18 and the
Chronic Kidney Disease–Epidemiology Collaboration
formula in adults.19 There were missing data for race,
uPCR, hematuria, serum albumin, and eGFR (see
Table 1 for frequencies).
Kidney International Reports (2019) 4, 1725–1734
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Table 1. Characteristics of IST-naïve patients at the time of biopsy
Characteristics

Adults
(n [ 324)

Children
(n [ 37)

P

Age at biopsy (yr)

53 (40, 63)

14 (12, 16)

<0.001

Follow-up time after biopsy (mo)

23 (10, 33)

0.006

122 (38)

21 (57)

0.02

Asian

28 (9)

1 (3)

Black/African American

Female

33 (18, 56)

Race

0.08
46 (14)

8 (22)

Native American

1 (0)

1 (3)

White/Caucasian

235 (73)

23 (62)

5 (2)

2 (5)

Multiracial

9 (3)

2 (5)

Hispanic ethnicity

Unknown

26 (8)

12 (32)

uPCR (g/g)

5.9 (3.5, 8.7)

3.0 (1.2, 7.1)

Unknown
Hematuria ($1þ)
Unknown
Serum albumin (g/dl)
Unknown
eGFR (ml/min per 1.73 m2)
Unknown
Thromboembolism before biopsy

102 (31)

8 (22)

122 (67a)

20 (77a)

141 (44)

11 (30)

2.6 (2.1, 3.5)

2.2 (1.6, 3.0)

95 (29)
83 (60, 106)

<0.001
0.005
0.25
0.005

3 (8)
107 (84, 128)

66 (20)

4 (11)

16 (5)

1 (3)

<0.001
0.54

eGFR, estimated glomerular ﬁltration rate; IST, immunosuppressive therapy; uPCR,
urinary protein-to-creatinine ratio.
a
Among those with available urinalysis results from time of kidney biopsy.
Continuous variables are expressed as median (interquartile range). Categorical variables are expressed as n (%).

Alignment With KDIGO Treatment Guidelines
KDIGO clinical practice guidelines for patients with
MN recommended IST if urinary protein excretion
exceeds 4 g/d AND remains at over 50% of the baseline
value AND is not progressively declining, during an
observation period of at least 6 months, but some exceptions were described.7 If IST is indicated, a 6-month
course of alternating monthly oral/i.v. GC and oral CYC
is recommended; a CNI (cyclosporine or tacrolimus) is
suggested for patients intolerant of, or with contraindications to, CYC.
We explored alignment of treatment practices for
CureGN participants with MN with KDIGO guidelines,
both for the overall cohort (primary analysis) and
among patients who underwent kidney biopsy either
after July 1, 2012, or after July 1, 2013 (i.e., 0 and 12
months, respectively), after the guidelines were published (sensitivity analysis). Patients who received a
ﬁrst-line IST other than CYC or a CNI were considered
to deviate from KDIGO guidelines. Among patients
who initiated IST <6 months following kidney biopsy,
we examined factors that might appropriately or
inappropriately have prompted earlier IST (i.e.,
severity of proteinuria/hypoalbuminemia, severity of
kidney impairment, duration of symptoms >6 months,
development of a thromboembolic event). Patients with
less than 6 months of follow-up between their biopsy
and their most recent study visit were excluded from
these analyses.
Kidney International Reports (2019) 4, 1725–1734
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Survey of Access to PLA2R Testing
A request to complete a survey regarding access to biopsy staining for PLA2R, and serum testing for antibodies to PLA2R, was distributed by e-mail to all CureGN
participating centers (n ¼ 70) in May 2018. A reminder email was sent in July 2018. CureGN investigators were
asked to complete the survey online. A copy of the survey is provided in the Supplementary Figure S1.
Statistical Analyses
Descriptive analyses were performed using frequencies
with percentages for categorical variables and medians
with interquartile ranges (IQRs) for continuous variables. Unadjusted comparisons across groups (adults
vs. children, treated vs. untreated) were made using c2
and Kruskal-Wallis testing, as appropriate. Times from
biopsy to initiation of ﬁrst-line IST, stratiﬁed by IST
regimen, were estimated using the Kaplan-Meier
method. Times from ﬁrst- to second-line IST, and the
composition of second-line IST strategies, were also
reported. All analyses were conducted using SAS
software (version 9.4; SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
A total of 419 patients (370 adults and 49 children) with
MN had been enrolled in CureGN at time of manuscript
preparation. Forty-six (12%) of these adults and 12
(24%) of these children received IST (other than a
maximum of 6 weeks of corticosteroids, in the case of
children) before kidney biopsy and were excluded
from our study cohort (Figure 1).
Baseline characteristics at time of biopsy for the 361
adults and children who were treatment-naïve at biopsy are presented in Table 1 (Supplementary Table S1
for data of the entire cohort). Median age at biopsy was
53 (IQR, 40–63) years in adults and 14 (IQR, 12–16)
years in children. Female sex was less frequent in
adults (38%) than children (57%), P ¼ 0.02. Most
adults and children self-reported as white. At biopsy,
comparing adults with children, median uPCR was
higher (5.9 vs. 3.0 g/g, P ¼ 0.005), and median eGFR
was lower (83 vs. 107 ml/min per 1.73 m2, P < 0.001).
Non-immunosuppressive Therapy Approaches
in Adults and Children
Among 324 IST-naïve adults, 93 (29%) were receiving
renin-angiotensin-aldosterone system blockade and 76
(23%) were receiving diuretics at time of biopsy. Thereafter, 274 (85%) and 208 (64%) ever received reninangiotensin-aldosterone system blockade or diuretics,
respectively, after a median of 33 (IQR, 18–56) months
postbiopsy. Among 37 IST-naïve children, 3 (8%) were
receiving renin-angiotensin-aldosterone system blockade
1727
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Screened (n = 4019)
Eligibility incomplete (n = 32)

Eligible for consent (n = 3318)

Ineligible* (n = 669)
- Local diagnosis (n = 223)
- Biopsy report and/or slides unavailable
- HIV (n = 21)
(n = 76)
- Active malignancy (n = 32)
- Patient lives in institutional setting (n = 10) - Systemic lupus erythematosus (n = 129)
- ESKD (n = 69)
- Biopsy > 5 years ago (n = 103)
- Diabetes (n = 181)
- Solid organ or bone marrow transplant (n = 35)
- Hepatitis B or C (n = 40)

Approached (n = 2860)

Not approached* (n = 458)
- Demonstrated past non-compliance/nonadherence (n = 88)
- Barriers to obtaining informed consent
(n = 23)
- Not approached per treating physician
(n = 75)

Consented (n = 2361)

- Waiting for consent (n = 157)
- Did not consent* (n = 342)
• Not interested (n = 173)
• Too much effort to get to center
(n = 78)
• Transportation issues (n = 29)
• Child care issues (n = 5)

-

Enrolled in NEPTUNE (n = 52)
Enrolled in another study (n = 7)
Not eligible per pathology pre-review
(n = 48)
Cohort closed (n = 39)
Other, specify (n = 199)

•
•
•
•
•

Work-related issues (n = 14)
Financial hardship (n = 4)
Refused biosamples (n = 24)
Other, specify (n = 86)
Did not provide reason (n = 15)

-

No enrollment visit > 6 months from consent (n = 25)
Enrolled and later deemed initial eligbility criteria not met (n = 34)
Central pathology diagnosis (n = 58)
Withdrawn from study before completing enrollment visit (n = 69)
• Lost to follow-up (n = 22)
• Withdrawn: participant choice (n = 32)
• Withdrawn: investigator’s discretion (n = 3)
• Withdrawn: other, specify (n = 12)

-

Incomplete/pending data entry (n = 47)

-

Other diagnosis (n = 1709)
• MCD (505)
• FSGS (n = 531)
• IgAN (n = 507)
• IgAV (n = 166)

Completed enrollment visit
(n = 2175)

Data entry complete (n = 2128)
MN (419)
<18 years old at biopsy (n = 49)
18+ years old at biopsy (n = 370)

Figure 1. Flowchart of included patients. Data as of June 5, 2018. *Could provide more than 1 reason. ESKD, end-stage kidney disease; FSGS,
focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; MCD, minimal change disease; MN, membranous nephropathy; NEPTUNE, Nephrotic Syndrome Study Network.

and 1 (3%) was receiving diuretics at time of biopsy.
Thereafter, 27 (73%) and 12 (32%) ever received reninangiotensin-aldosterone system blockade or diuretics,
respectively, after a median of 23 (IQR, 10–33) months.
IST Approaches in Adults
Among 324 IST-naïve adults at time of kidney biopsy,
244 (75%) initiated IST at any time during a median
follow-up of 33 (IQR, 18–56) months, and 167 (55%) of
the 302 adults with at least 6 months of follow-up after
kidney biopsy had initiated IST within the ﬁrst 6
months following kidney biopsy (Table 2). The median
time from biopsy to IST initiation was 4.3 months.
1728

Focusing on any exposure to IST, 176 (54%) of adults
were ever exposed to GC, either alone (8%) or consecutively/concurrently (92%) with other IST (Table 2).
Thereafter, CNIs, RTX, and CYC were the most frequently
prescribed ISTs (44%, 31%, and 27% exposed, respectively), followed by MMF, adrenocorticotropic hormone,
and azathioprine (10%, 7%, and <1%, respectively).
Single-agent oral GCs were used earliest in the
disease course (median 31 days from kidney biopsy;
IQR, 9–175 days), followed by CNI-based regimens
(Figure 2).
Focusing on ﬁrst-line IST, CNI-based regimens were
the most frequently prescribed (40% of the 244 treated
Kidney International Reports (2019) 4, 1725–1734
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Table 2. Exposure to IST among adults and children who were
IST-naïve at time of kidney biopsy
Adults
(n [ 324)

Children
(n [ 37)

P

Any IST

244 (75)

26 (70)

0.45

Steroids

176 (54)

21 (57)

0.78

Oral steroids

169 (52)

20 (54)

0.83

I.v. steroids

30 (9)

2 (5)

0.43

Calcineurin inhibitors

142 (44)

16 (43)

0.95

Mycophenolate mofetil

33 (10)

6 (16)

0.26

Cyclophosphamide

87 (27)

1 (3)

0.001

83 (26)

1 (3)

0.002

Ever treated

Oral CYC
I.v. CYC
Rituximab
Azathioprine
ACTH
RAAS-blockade

10 (3)

0 (0)

0.28

102 (31)

6 (16)

0.05

1 (0)

0 (0)

0.74

23 (7)

0 (0)

0.09

274 (85)

27 (73)

0.07

ACE-inhibitors

144 (44)

24 (65)

0.02

Angiotensin receptor blockers

147 (45)

7 (19)

0.002

208 (64)

12 (32)

<0.001

Adults
(n ¼ 302)

Children
(n ¼ 31)

Any IST

167 (55)

18 (58)

0.85

Steroids

112 (37)

12 (39)

0.86

Oral steroids

109 (36)

12 (39)

0.77

I.v. steroids

8 (3)

0 (0)

0.36

Calcineurin inhibitors

86 (28)

11 (35)

0.41

Mycophenolate mofetil

10 (3)

4 (13)

0.01

Cyclophosphamide

47 (16)

0 (0)

0.02

42 (14)

0 (0)

0.03

6 (2)

0 (0)

0.43

31 (10)

3 (10)

0.92

Diuretics
Treated in the ﬁrst 6 months after biopsya

Oral CYC
I.v. CYC
Rituximab
Azathioprine

1 (0)

0 (0)

0.75

ACTH

4 (1)

0 (0)

0.52

RAAS-blockade

172 (57)

17 (55)

0.82

ACE-inhibitors

91 (30)

15 (48)

0.04

Angiotensin receptor blockers

82 (27)

2 (6)

0.01

131 (43)

5 (16)

0.003

Diuretics

ACE, angiotensin converting enzyme; ACTH, adrenocorticotropic hormone; CYC,
cyclophosphamide; IST, immunosuppressive therapy; MN, membranous nephropathy;
RAAS, renin-aldosterone-angiotensin system.
a
Cohort restricted to those with at least 6 months of follow-up.
Categorical variables expressed as n (%).

adults; Table 3). Thereafter, 49 patients (20% of treated
adults) received single-agent GC for at least 30 days as
their ﬁrst-line IST. Frequency of use as ﬁrst-line IST
was similar for both RTX and CYC (15% and 16% of
treated adults, respectively). Other ISTs, including
MMF, adrenocorticotropic hormone, and azathioprine,
were much less frequently prescribed as a ﬁrst-line IST
(4%, 0%, and 0%, of patients, respectively). Overall,
among the 244 adults who ever received IST, only 138
(57%) received either CYC or a CNI. Restricting the
cohort to adults biopsied on or after July 1, 2013, did
not reveal any meaningful differences (102 of 179 patients, 57%).
Focusing on second-line IST, 118 (48%) of the 244
adults who started a ﬁrst-line IST ultimately
Kidney International Reports (2019) 4, 1725–1734
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transitioned to a second-line IST, after a median of 5
months (range, 1–71 months) (Supplementary
Table S2A). The proportion of patients proceeding to
a second-line IST was highest for single-agent GC (71%
of patients), intermediary for CNI-, CYC-, or MMFbased regimens (48%, 47%, and 50% of patients,
respectively), and lowest for RTX-based regimens (27%
of patients), P < 0.001. Time from initiation of ﬁrst-line
IST to initiation of second-line IST was shortest for
single-agent GC (median, 68 days; IQR, 35–131 days) or
MMF-based regimens (median, 64 days; IQR, 45–287
days), and longest for CNI-based regimens (median, 328
days; IQR, 135–622 days). To account for differences in
follow-up time between groups, hazards for transitioning to second-line IST were compared across ﬁrstline IST groups. Comparing with CYC-based regimens,
hazard ratios (HRs) for transitioning to a second-line
IST were signiﬁcantly higher for single-agent GC
(HR, 3.4; 95% conﬁdence interval, 1.9–6.0) but similar
for other comparator ﬁrst-line IST strategies: CNI-based
HR 1.0 (95% conﬁdence interval, 0.6–1.7), RTX-based
HR 0.6 (95% conﬁdence interval, 0.3–1.4), and MMFbased HR 0.9 (95% conﬁdence interval, 0.4–2.4).
With respect to the choice of second-line IST, substantial variability was evident (Supplementary
Table S2A).
IST Approaches in Children
Among 37 IST-naïve children (allowing inclusion of
children with a maximum of 6 weeks of GC monotherapy immediately before kidney biopsy), 26 (70%)
initiated IST at any time during a median follow-up of
23 (IQR, 10–33) months, and 22 (59%) of 31 children
with at least 6 months of follow-up following kidney
biopsy initiated IST within the ﬁrst 6 months after
kidney biopsy. The median time from biopsy to IST
initiation was 1.9 months.
Focusing on any exposure to IST, 21 (57%) of 37
children were ever exposed to GC, either alone (24%)
or consecutively/concurrently with other treatments
(76%; Table 2). Thereafter, CNIs (43%), MMF (16%),
and RTX (16%) were the most frequently prescribed
ISTs, followed by CYC, adrenocorticotropic hormone,
and azathioprine (3%, <1%, and <1%, respectively).
Single-agent oral GCs were used earliest in the disease
course (median 3 days from kidney biopsy; IQR, 27 to
59 days), followed by RTX- and CNI-based regimens
(Figure 2).
Focusing on ﬁrst-line IST, CNI-based regimens were
the most frequently prescribed (46% of the 26 treated
children; Table 3). Thereafter, 7 children (27% of
treated children) received at least 30 days of singleagent GC as ﬁrst-line IST: 3 had started GC before
kidney biopsy and IST was transitioned to another IST
1729
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Figure 2. Time to immunosuppressive therapy (IST) initiation after biopsy among adults (a) and children (b) with membranous nephropathy who
were IST-naïve at the time of kidney biopsy. Any IST also includes adrenocorticotropic hormone and azathioprine.

within 30 days after biopsy; however, the remaining 4
initiated single-agent GC after conﬁrming a diagnosis of
MN by kidney biopsy. Frequency of use as ﬁrst-line
IST was higher for RTX than MMF (15% and 8% of
treated children, respectively), whereas CYC, adrenocorticotropic hormone, and azathioprine were much
less frequently prescribed as ﬁrst-line IST (<1% of
patients) in children. Overall, among the 26 children
who ever received IST, only 12 (46%) received a CNI or
CYC (none received CYC), as recommended by KDIGO,
as a ﬁrst-line IST. Restricting the analysis to children
who were biopsied on or after July 1, 2013, did not
Table 3. First-line IST in adults and children who were treatmentnaïve at time of kidney biopsy

First therapy

n (%)

Days from biopsy
until onset,
median (IQR)

Days from biopsy
until onset,
range

Adults, n ¼ 324
Never received therapya

80 (25)

N/A

N/A

CNI-based Therapy

98 (30)

88 (18, 202)

2–1700

Steroids alone

49 (15)

31 (9, 175)

0–2049

CYC-based therapy

40 (12)

61 (18, 153)

0–855

Rituximab-based therapy

37 (11)

133 (75, 277)

15–1964

MMF-based therapy

14 (4)

72 (11, 384)

6–1016

Combination of ISTs

6 (2)

69 (26, 132)

14–207

Children, n ¼ 37
Never received therapya

11 (30)

N/A

N/A

CNI-based therapy

12 (32)

43 (15, 173)

4–324
30 to 96

Steroids alone

7 (19)

3 (27, 59)

Rituximab-based therapy

4 (11)

37 (20, 272)

4–506

MMF-based therapy

2 (5)

57 (13, 100)

13–100

Combination of ISTs

1 (3)

2 (2, 2)

2–2

ACTH, adrenocorticotropic hormone; CNI, calcineurin inhibitor; CYC, cyclophosphamide;
IST, immunosuppressive therapy; MMF, mycophenolate mofetil; N/A, not applicable.
a
Never received any of the following therapies: steroids (oral or i.v.), calcineurin inhibitors, mycophenolate mofetil, cyclophosphamide (oral or i.v.) rituximab, azathioprine,
ACTH. A new therapy started within 30 days of a previous therapy is considered to start
at the same time.
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reveal any meaningful differences (11 of 24 children,
46%). Focusing on second-line IST, 7 (27%) of the 26
children who started a ﬁrst-line IST ultimately transitioned to a second-line IST (Supplementary Table S2B).
Comparison of Patients Treated Versus Not
Treated With IST During the First 6 Months
Following Kidney Biopsy
Restricting the cohort to patients with at least 6 months
of follow-up following kidney biopsy (n ¼ 302 adults
and n ¼ 31 children), we compared characteristics
between patients who did versus did not initiate IST
within the ﬁrst 6 months following kidney biopsy
(Table 4). Aside from a higher proportion of male individuals in the treated group (32% vs. 47% female
sex, P ¼ 0.008), adults treated with IST within the ﬁrst
6 months following kidney biopsy were demographically similar to adults who were not treated. However,
treated adults had more severe biochemical features of
the nephrotic syndrome, with a higher median uPCR
(7.0 vs. 3.8 g/g; P < 0.001) and a lower median serum
albumin (2.3 vs. 3.2 g/dl; P < 0.001) at time of biopsy.
The proportion of adults with a uPCR 8 to 12 g/g or
>12 g/g at biopsy was also higher in the treated group,
although 21 (17%) patients who received IST earlier
than 6 months following kidney biopsy had a uPCR <4
g/g before IST initiation. The proportion of patients
with an eGFR <30 ml/min per 1.73 m2 was low in both
groups (8 [6%] of treated and 7 [7%] of untreated patients, P ¼ 0.22). Adults who were treated versus untreated within the ﬁrst 6 months following biopsy were
not any more likely to have had a thromboembolic
event (15 [9%] vs. 11 [8%]; P ¼ 0.80).
In contrast to the adult population, uPCR and serum
albumin levels were very similar among children who
Kidney International Reports (2019) 4, 1725–1734
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Table 4. Characteristics of adults and children with MN who were IST-naïve at time of kidney biopsy and who had at least 6 months of
follow-up after kidney biopsy, comparing those who were treated versus untreated with IST within the ﬁrst 6 months following kidney biopsy
Adults (n [ 302)

Children (n [ 31)

Treated (n [ 167)

Untreated (n [ 135)

P

Treated (n [ 18)

Untreated (n [ 13)

P

Age at biopsy (yr)

53 (42, 63)

53 (40, 63)

0.76

15 (11, 16)

14 (12, 15)

0.70

Follow-up time after biopsy (mo)

33 (19, 54)

40 (22, 60)

0.13

23 (13, 32)

30 (28, 38)

0.05

Time from biopsy to IST

1 (0, 3)

N/A

N/A

2 (0, 3)

N/A

N/A

Time from symptom onset to IST

5 (3, 8)

N/A

N/A

1 (0, 1)

N/A

N/A

61 (37)

N/A

N/A

2 (11)

N/A

N/A

53 (32)

63 (47)

0.008

9 (50)

9 (69)

0.28

Asian

15 (9)

12 (9)

0 (0)

1 (8)

Black/African American

3 (23)

Characteristics

More than 6 mo from symptom onset to IST
Female
Race

0.70

0.22

27 (16)

17 (13)

4 (22)

Native American

0 (0)

1 (1)

0 (0)

1 (8)

White/Caucasian

120 (72)

98 (73)

13 (72)

5 (38)

Multiracial

2 (1)

2 (1)

1 (5)

1 (8)

Unknown

3 (2)

5 (4)

0 (0)

2 (15)

uPCR at biopsy (g/g)

7.0 (4.9, 9.6)

3.8 (2.1, 6.0)

<0.001

3.3 (1.2, 7.4)

3.4 (1.3, 4.6)

<4

21 (17)

42 (53)

7 (50)

4–7.9

53 (43)

27 (34)

4 (29)

2 (20)

8–11.9

35 (28)

7 (9)

1 (7)

1 (10)

15 (12)

4 (5)

2 (14)

0 (0)

$12
uPCR before IST onset (g/g)

6.9 (5.0, 9.5)

N/A

N/A

N/A

N/A

<4

20 (17)

N/A

N/A

5 (36)

N/A

N/A

4–7.9

51 (44)

N/A

N/A

5 (36)

N/A

N/A

8–11.9

30 (26)

N/A

N/A

1 (7)

N/A

N/A

$12

14 (12)

N/A

N/A

3 (21)

N/A

N/A

Hematuria ($1þ) at biopsya

71 (75)

38 (54)

0.04

11 (92)

6 (67)

0.33

Serum albumin at biopsy, g/dl

2.3 (1.9, 3.0)

3.2 (2.5, 4.0)

<0.001

2.3 (1.6, 3.0)

2.1 (1.8, 3.0)

0.88

eGFR at biopsy, ml/min per 1.73 m2

81 (57, 103)

88 (62, 108)

0.22

116 (89, 133)

100 (84, 114)

0.52

eGFR at biopsy <30

8 (6)

7 (7)

5.8 (1.0, 8.7)

0.60

7 (70)

1 (6)

0 (0)

Thromboembolism
Before biopsy

8 (5)

7 (5)

0.88

0 (0)

0 (0)

0.99

In 6 mo postbiopsyb

7 (4)

4 (3)

0.58

1 (5)

0 (0)

0.39

eGFR, estimated glomerular ﬁltration rate; IST, immunosuppressive therapy; MN, membranous nephropathy; N/A, not applicable; uPCR, urinary protein-to-creatinine ratio.
a
Among those with hematuria data at biopsy.
b
Among those without thromboembolism before biopsy.
Continuous variables are expressed as median (interquartile range). Categorical variables are expressed as n (%).

were treated versus untreated in the 6 months
following kidney biopsy. Restricting to patients who
were biopsied after July 1, 2012, or July 1, 2013, did
not reveal any meaningful differences in median time
to ﬁrst IST, the proportion of patients who received IST
within 6 months following kidney biopsy, or the proportion of patients who received either a CYC- or CNIbased regimen as ﬁrst-line IST (although fewer patients
received MMF and more received RTX in the more
recent eras), despite overall similar laboratory measures
of disease severity when compared with earlier cohorts
(Supplementary Table S3).
Survey of Access to PLA2R Testing
A total of 31 centers (44%) responded to the survey
between May 22, 2018 and August 21, 2018. They were
all from the United States and Canada. Most (n ¼ 26,
84%) routinely used anti-PLA2R blood testing,
although only 7 of the 26 (27%) performed the testing
locally. The earliest reported introduction date for
Kidney International Reports (2019) 4, 1725–1734

anti-PLA2R blood testing was January 2014. PLA2R
antigen staining by kidney biopsy was also used
routinely in most centers (n ¼ 25, 81%). In contrast to
blood testing, most centers (21 of 25, 84%) performed
this testing locally. The earliest reported introduction
date for PLA2R antigen testing by kidney biopsy was
June 2013.
DISCUSSION
In this international cohort of 419 prevalent adults and
children with MN enrolled in CureGN, we identiﬁed
frequent and early use of IST and generally poor
alignment with KDIGO clinical practice guidelines.
Among the 361 patients (324 adults and 37 children)
who were treatment-naïve before kidney biopsy, more
than half initiated IST within 6 months after kidney
biopsy, despite KDIGO recommendations to “watch
and wait” for at least 6 months to observe for spontaneous remission. Among those patients who ever
1731
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received IST (75% of adults and 70% of children), only
57% of adults and 46% of children received a CYC- or a
CNI-based regimen as ﬁrst-line IST, despite KDIGO
recommendations to use these agents as ﬁrst- and
second-line IST, respectively. We further identiﬁed GC
monotherapy as ﬁrst-line IST for MN in a signiﬁcant
proportion of patients (20% of treated adults and 27%
of treated children), despite proven inefﬁcacy for
MN.20 Not surprisingly, the response rate for GC
monotherapy as ﬁrst-line IST also appeared to be
poorer than for other ISTs within our cohort (71% of
adults required a second-line agent, with an HR for
requiring transition to a second-line agent of 3.4 when
compared with CYC).
In this cohort, the median time from biopsy to IST
initiation in adults was 4.3 months. When exploring
possible explanations for earlier than recommended use
of IST, we identiﬁed a number of ﬁndings. Among
adults, 37% of patients who were treated earlier than 6
months following kidney biopsy had reported symptoms of nephrotic syndrome for longer than 6 months;
thus, nephrologists might have been satisﬁed that the
patient had already failed to enter remission spontaneously after 6 months of observation. Next, many of
the adults treated earlier than 6 months after kidney
biopsy had heavy proteinuria at the time of kidney
biopsy (40% of treated vs. 14% of untreated patients
had a uPCR of $8 g/g), and serum albumin was also
lower in the treated group (median 2.3 vs. 3.2 g/dl):
thus, severe and symptomatic nephrotic syndrome
might have triggered IST initiation in these patients.
Finally, 9% of patients treated with IST earlier than 6
months following kidney biopsy had experienced a
thromboembolic event before or in the 6 months
following kidney biopsy, representing a strong indication to initiate IST without delay. Overall, 44% of
the 167 adults treated within the ﬁrst 6 months after
kidney biopsy had 1 or more identiﬁable relative
indication for earlier IST initiation (i.e., symptom
duration >6 months, a uPCR $8 g/g, or a thromboembolic event), whereas 30% lacked any of these indications (representing potential deviations from
KDIGO guidelines), and 26% had insufﬁcient data for
evaluation (i.e., missing symptom duration or uPCR
data). Conversely, 20% of adults treated <6 months
after biopsy had no indication for, or a possible
contraindication to, IST initiation according to KDIGO
guidelines (17% had a uPCR <4 g/g at biopsy, and 6%
had an eGFR <30 ml/min per 1.73 m2 at biopsy,
whereas 15% satisﬁed both these criteria). No signiﬁcant differences between children treated versus untreated with IST in the ﬁrst 6 months following kidney
biopsy were identiﬁed, and numbers were too small to
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derive meaningful conclusions regarding guideline
adherence.
Our study is not without limitations. First, because
much of our data came from chart extraction and patient interview regarding events that happened before
study enrollment, we can only speculate regarding the
exact reasons for earlier use of IST or IST choice.
Although we could extract information regarding
biochemical features of nephrotic syndrome, eGFR, and
thromboembolic events for most patients, laboratory
data were missing for some patients and severity of
symptoms was missing for all patients, hampering our
ability to truly determine the appropriateness of decisions whether and when to treat with IST. Nevertheless, we hypothesize that use of CNIs as ﬁrst-line
therapy in almost one-third of patients might have
inﬂuenced the decision to start IST earlier than recommended, as CNIs are generally considered safer than
CYC. Indeed, CYC was used rarely in our study population, especially in children, whereas RTX (which, at
the time these patients were treated, had only been
studied in case reports and series) was used more
frequently than expected. It is worth noting, however,
that some of the patients enrolled in CureGN were also
enrolled in the MENTOR study of RTX use in MN.16
Conceivably, in a treatment era that appears to have
moved away from CYC as ﬁrst-line IST for MN, in favor
of “less toxic” CNI- or RTX-based regimens, a 6-month
waiting period as recommended by KDIGO might be
considered too long for many nephrologists and their
persistently nephrotic patients. Indeed, the experience
of CureGN participants highlights a potential need to
reconsider current guideline recommendations
regarding IST timing and choice. Finally, the inﬂuence
of anti-PLA2R antibody levels on decisions regarding
IST necessity and timing requires further exploration:
although we did collect data regarding the general
availability of testing for PLA2R at study sites, we did
not collect data on whether testing was performed, and
how it inﬂuenced decision-making, in each of the individual study participants.
Our study also illuminates understanding of MN
treatment patterns in children, in whom MN is rare and
randomized controlled treatment trials are lacking.21,22
Indeed, treatment recommendations for children with
MN are extrapolated from adult data, despite higher
rates of spontaneous remission, lower rates of PLA2R
positivity,23,24 and more favorable renal outcomes25,26 in
children compared with adults. Uncertainty with
respect to IST choice in children with MN is reﬂected in
the wide variety of ﬁrst-line IST choices observed in this
cohort. Children rarely received CYC, which we hypothesize is due to concerns for toxicity, including
Kidney International Reports (2019) 4, 1725–1734
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sterility. Further, the lack of discernible differences
between children who were versus were not treated
with IST within the ﬁrst 6 months following biopsy
suggests that consensus regarding indications for early
treatment with IST in children is lacking. Accordingly,
CureGN is now uniquely positioned to prospectively
monitor outcomes and treatment responses in children
with MN, which in turn can inform future clinical trials.
To conclude, we have described practice patterns
with respect to the timing and choice of IST among a
large cohort of adults and children with biopsy-proven
MN. We report that only half of treated patients
received a CNI- or CYC-based regimen as ﬁrst-line IST,
that 1 in 5 treated patients received GC monotherapy as
ﬁrst-line IST, and that RTX was more frequently prescribed than CYC in our patient cohort, representing
apparent major deviations from KDIGO guidelines.
Further, we report that more than half of patients in
our cohort initiated IST <6 months following kidney
biopsy: while many of these patients had an apparent
indication for earlier treatment (i.e., symptoms for more
than 6 months, severe nephrotic syndrome, or a
thromboembolic event), 1 in 5 had an apparent
contraindication to receiving IST (i.e., a uPCR <4 g/g
or an eGFR <30 ml/min per 1.73 m2). We consider these
ﬁndings to represent a lack of awareness of, or conﬁdence in, current KDIGO guidelines, factors that should
be considered when updating these guidelines. Finally,
we report widespread access to PLA2R testing among
CureGN investigators and propose that future treatment guidelines incorporate available data regarding
the role of PLA2R testing in determining the necessity
and timing of IST initiation.
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